Amphastar Pharmaceuticals (AMPH) Announces Quarterly Earnings Results

Share on StockTwits

Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its earnings results on Thursday. The company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.01, Briefing.com reports. The company had revenue of $75.54 million during the quarter, compared to analyst estimates of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. Amphastar Pharmaceuticals’s revenue was up 30.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share.

Shares of NASDAQ AMPH traded up $0.88 during midday trading on Friday, hitting $21.59. The company’s stock had a trading volume of 735,306 shares, compared to its average volume of 117,925. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94. Amphastar Pharmaceuticals has a 1 year low of $14.40 and a 1 year high of $21.65. The firm has a market cap of $890.44 million, a price-to-earnings ratio of 56.82, a PEG ratio of 8.77 and a beta of 1.38.

Several brokerages have weighed in on AMPH. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 13th. Needham & Company LLC lowered their target price on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Friday. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $23.00.

In other news, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total value of $178,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason B. Shandell sold 16,095 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $20.99, for a total transaction of $337,834.05. Following the completion of the transaction, the general counsel now directly owns 204,805 shares of the company’s stock, valued at approximately $4,298,856.95. The disclosure for this sale can be found here. In the last three months, insiders sold 28,502 shares of company stock valued at $558,373. Insiders own 31.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3928907/amphastar-pharmaceuticals-amph-announces-quarterly-earnings-results.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: Why do company’s buyback their stock?

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Wix.Com  Shares Up 6.3%
Wix.Com Shares Up 6.3%
Fabrinet  CEO Sells $313,414.74 in Stock
Fabrinet CEO Sells $313,414.74 in Stock
Superior Industries International Inc  CEO Donald J. Stebbins Acquires 31,249 Shares
Superior Industries International Inc CEO Donald J. Stebbins Acquires 31,249 Shares
Agenus  Shares Up 6.3%
Agenus Shares Up 6.3%
Tellurian Inc  Director Buys $212,400.00 in Stock
Tellurian Inc Director Buys $212,400.00 in Stock
LivePerson, Inc.  Given Consensus Recommendation of “Buy” by Brokerages
LivePerson, Inc. Given Consensus Recommendation of “Buy” by Brokerages


Leave a Reply

© 2006-2018 Ticker Report